1 |
Pooladanda V, Thatikonda S, Godugu C. The current understanding and potential therapeutic options to combat COVID-19. Life Sci 2020;254:117765. [PMID: 32437797 DOI: 10.1016/j.lfs.2020.117765] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
|
2 |
Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
3 |
Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Reference Citation Analysis]
|
4 |
Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. RRCT 2019;14:173-82. [DOI: 10.2174/1574887114666190306154650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
|
5 |
Wu W, Lin J, Xiao J, Cao Y, Ma Y. Recent Advances in the Synthesis of CF 3 ‐ or HCF 2 ‐Substituted Cyclopropanes. Asian J of Organic Chemis 2021;10:485-95. [DOI: 10.1002/ajoc.202000723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|